Literature DB >> 7826833

Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.

K T Seng1, C E Tiong, T C Hiang.   

Abstract

A randomised double-blind crossover study was undertaken to compare the anti-emetic efficacy of alizapride against high dose metoclopramide. A total of 32 patients on cisplatin were randomised to receive either high dose metoclopramide (7 mg kg-1 day-1) or alizapride (5 mg kg-1 day-1). Anti-emetic responses in terms of control of vomiting episodes were similar in both regimens (59%). However, patients showed a statistically significant preference for high dose metoclopramide (P = 0.02). Side effects of both regimens were minimal. We conclude that alizapride is not superior to high dose metoclopramide in controlling cisplatin induced vomiting.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7826833      PMCID： PMC1364803          DOI： 10.1111/j.1365-2125.1994.tb04355.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  8 in total

1.  Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.

Authors:  D Cunningham; M Soukop; N L Gilchrist; G J Forrest; A Hepplestone; I T Calder; C S McArdle; A W Hutcheon; S B Kaye
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

2.  [Evaluation of a new antiemetic, alizapride, in cancerology (author's transl)].

Authors:  D Cupissol; F Favier; C Favier; B Serrou
Journal:  Sem Hop       Date:  1982-06-03

3.  A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin.

Authors:  P M Parikh; B S Charak; S D Banavali; S B Koppikar; N Giri; P Nadkarni; T K Saikia; R Gopal; S H Advani
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

4.  Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.

Authors:  P S Warrington; S G Allan; M A Cornbleet; J S MacPherson; J F Smyth; R C Leonard
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-22

5.  The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.

Authors:  R A Joss; R L Galeazzi; A K Bischoff; M Pirovino; H J Ryssel; K W Brunner
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

6.  On the receiving end--patient perception of the side-effects of cancer chemotherapy.

Authors:  A Coates; S Abraham; S B Kaye; T Sowerbutts; C Frewin; R M Fox; M H Tattersall
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

7.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

8.  Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.

Authors:  R Saller; D Hellenbrecht
Journal:  Cancer Treat Rep       Date:  1985-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.